Cerevel Corporate Presentation - September

2Q 2022 Financial Results & Business Update

IARPD 2022 Poster - Setting the TEMPO: A Phase 3 Program to Investigate Tavapadon, a Selective D1/D5 Partial Agonist, for Parkinson’s Disease

1Q 2022 Financial Results & Business Update

SIRS 2022 Presentation – Emraclidine as a Novel Positive Allosteric Modulator Targeting M4 Muscarinic Receptors: Results From a Phase 1b Trial in Patients With Schizophrenia

AAN 2022 Presentation - Darigabat: pronounced antiepileptic activity in the mesial temporal lobe mouse model of drug-resistant focal epilepsy

AAN 2022 Poster - Ensuring the Continuity of Data Collection in a Focal Epilepsy Clinical Trial During the COVID-19 Pandemic

AAN 2022 Poster - Pharmacokinetics, Pharmacodynamics, and Safety of the Highly Selective Dopamine D1/D5 Agonist Tavapadon: Summary of Early Phase Clinical Studies

AAN 2022 Poster - Levodopa and Dopamine Agonist Medication Utilization among Patients with Parkinson’s Disease Enrolled in Commercial and Medicare Advantage Part D Health Plans

4Q 2021 Financial Results & Business Update